Blood ctDNA testing to monitor treatment in children and young adults with classical Hodgkin lymphoma
Official title: Non-interventional Research Protocol Involving Human Participants
Run by Assistance Publique - Hôpitaux de Paris · NCT07356882 · Data updated 2026-11-12
This project tests whether a blood test that detects circulating tumor DNA can monitor treatment response and help predict relapse in children and young adults with classical Hodgkin lymphoma.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | November 24, 2025 |
| Main results expected | November 2029 |
| Study ends | November 2029 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT07356882 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and young adults under 25 with newly diagnosed classical Hodgkin lymphoma who can provide consent and be followed at participating centers are the ideal candidates.
✕Probably not a fit
Patients with nodular lymphocyte predominant Hodgkin lymphoma, prior chemotherapy/radiotherapy for another cancer, or those living outside participating countries where follow-up cannot be ensured are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational European project uses plasma-based circulating tumor DNA (ctDNA) analysis as a non-invasive biomarker in pediatric classical Hodgkin lymphoma. Blood samples will be collected at diagnosis and during therapy to detect recurrent mutations and measure molecular tumor burden, with results compared to PET/CT and clinical outcomes. The aim is to refine risk stratification by identifying patients at higher risk of relapse early and those who might safely receive less intensive therapy. The project is nested in pediatric cooperative networks and uses centralized molecular testing with planned long-term follow-up.
Why it matters
Potential benefit: If successful, this approach could identify high-relapse patients earlier and guide more personalized therapy to reduce overtreatment and long-term side effects.
How similar studies have gone: Similar ctDNA approaches have shown feasibility and prognostic value in adult cHL and early pediatric pilot work (e.g., the HOLY study) with high baseline mutation detection and correlation with PET/CT.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed classical Hodgkin lymphoma (cHL) * Children and young adults under the age of 25 years old * Signature of informed consent by the patient and/or holders of parental authority (depending on the age of the patient) * Affiliation to a social security scheme or being beneficiary of such a scheme Exclusion Criteria: * Previous treatment with chemotherapy or radiotherapy for another cancer * Pretreatment of Hodgkin lymphoma (except one treatment with corticosteroid for 7 to 10 days for large or compressive mediastinal tumors). * Diagnosis of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) * Other concomitant malignancies • Residence outside participating countries in for which long-term follow-up cannot be ensured
Where it's running
-
Pediatric Hematology and Oncology Department
Paris, France Recruiting
Study contacts
- Principal investigator: Mathieu SIMONIN, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Mathieu SIMONIN, Medical Doctor
- Email: mathieu.simonin@aphp.fr
- Phone: 00 33 1 44 73 66 04
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sintilimab combined with AVD chemotherapy for treating pediatric Hodgkin lymphoma
This study is testing if a new immunotherapy combined with standard chemotherapy can help children and teens with low-to-intermediate risk Hodgkin lymphoma feel better and improve their treatment results.
-
Assessing Prognosis in Hodgkin Lymphoma
This study is trying to find better ways to predict how Hodgkin Lymphoma will progress in patients who have finished treatment or have had a relapse, using new tools and tests to help personalize their care.
-
Using Brentuximab Vedotin to treat newly diagnosed Classical Hodgkin Lymphoma in young patients
This study is testing if a new treatment with Brentuximab vedotin can help young patients with newly diagnosed classical Hodgkin lymphoma feel better while reducing the need for chemotherapy and radiation.
-
Healthy Lifestyle Plan for Lymphoma Survivors
This study is testing whether a special health plan that includes lifestyle changes and nutrition advice can help lymphoma survivors feel better after they've been in remission for a while.
-
Combining pembrolizumab with chemotherapy for relapsed Hodgkin lymphoma
This study is testing if adding pembrolizumab to standard chemotherapy can help people with relapsed Hodgkin lymphoma feel better and have fewer side effects.
-
Individualized immunotherapy for early-stage Hodgkin lymphoma
This study is testing a personalized treatment using a new drug for young people with early-stage Hodgkin lymphoma to see if it can help them avoid harsh chemotherapy and improve their quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.